Protara Therapeutics to Participate in Upcoming Investor Conferences
- Cowen 42nd Annual
Health Care Conferenceon March 9, 2022at 9:10am ET
- Oppenheimer 32nd Annual Healthcare Conference on
March 15, 2022at 2:00pm ET
A live webcast of the fireside chats can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcasts will be archived on the Company’s website for 90 days following the presentations.
Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.
Source: Protara Therapeutics